AEVUM // SURGICAL
Subscribe
Aevum Surgical · Hong Kong · Greater Bay Area
StageSeed · 2026
Anchor partnerPolyU × PUTH
Quality systemISO 13485

Seed Round · 2026
Robotic precision.
None of the bulk.

Aevum is reimagining the surgical robot as handheld instruments — robotic precision and articulation beyond the freehand, for minimally-invasive and natural-orifice (NOTES) procedures, at a fraction of a console’s cost and footprint.

Subscribe for updates ↗ See the solution
Surgeon operating with a handheld instrumentSurgeon operating with a handheld instrument
Approach Compact · Handheld
[ Handheld surgical robot · Concept ]

Robotic precision, in a
handheld instrument.

Procedures
NOTES
Natural-orifice & minimally-invasive surgery — hand-operated, no console.
Market growth
15–20% CAGR
APAC outpacing the global average.
Today’s consoles
1–2MUSD+
Capital cost of a da Vinci-class console. Aevum: a fraction.
Footprint
Compact
Handheld. No cart, console or OR retrofit.
Robotic precision Handheld instruments NOTES — natural-orifice surgery Motion beyond the freehand A fraction of the cost No console or OR retrofit PolyU × Peking University Third Hospital Industry 5.0–ready ISO 13485 Hong Kong · Greater Bay Area Robotic precision Handheld instruments NOTES — natural-orifice surgery Motion beyond the freehand A fraction of the cost No console or OR retrofit PolyU × Peking University Third Hospital Industry 5.0–ready ISO 13485 Hong Kong · Greater Bay Area
// 01 The Problem

Surgical robotics is stuck
at the top of the market.

Today's platforms are large, complex master–slave systems — brilliant on capability, out of reach for most operating rooms.

Large console-based surgical robot in a hospital theatreLarge console-based surgical robot in a hospital theatre
Legacy console master–slave

Precision was solved.
Accessibility was not.

Console robots demand dedicated OR space, infrastructure changes and months of certification — so adoption stays concentrated in top-tier urban hospitals while mid-tier and emerging markets go underserved.

Capital cost
1–2MUSD+
Per unit, plus per-procedure consumables.
Training burden
Months
Of surgeon certification before clinical use.
Footprint
Multi-cart
Dedicated OR space and infrastructure modifications.
The next step in surgical evolution — each step: less invasive, more precise, more accessible
01Open surgeryDirect access
02MIS multiportLaparoscopic
03Single-incisionSILS
04Natural orificeNOTES
05RoboticConsole / master–slave
06 · AevumHandheld roboticRobotic precision · handheld
// 02 The Solution

Robotic surgery,
radically simplified.

Robotic control and precision in compact, hand-operated instruments — without the cost, footprint or setup of a master–slave console.

Surgeon's hands operating an instrumentSurgeon's hands operating an instrument S.01 · Precision

Beyond the hand

Capstan-driven articulation gives control and steadiness beyond the freehand instrument — the precise, scaled motion robotic surgery is prized for.

Motion beyond the hand↗
Ergonomic instrument conceptErgonomic instrument concept S.02 · NOTES

Natural-orifice
ready

Compact enough to bring robotic capability to minimally-invasive, single-incision and natural-orifice (NOTES) procedures — through the smallest possible access.

NOTES · single-incision↗
Precision actuation mechanismPrecision actuation mechanism S.03 · Mechanism

Capstan-driven
articulation

A motor pack integrated within the instrument body drives capstan articulation for precise, responsive actuation.

Precision actuation↗
Accessible operating roomAccessible operating room S.04 · Cost

A fraction of
the cost

Lower capital cost, a smaller footprint and far simpler setup than a console — robotic surgery mid-tier and emerging hospitals can actually adopt.

Easy setup↗
Surgeon retaining tactile feedbackSurgeon retaining tactile feedback S.05 · Feel

Surgeon-
centric

Preserves the tactile and visual feedback that master–slave loops lose. The surgeon stays in direct contact with the operative field.

Tactile + visual↗
Connected, data-driven surgeryConnected, data-driven surgery S.06 · Intelligence

Industry 5.0–
ready

AI motion guidance, connectivity and surgical data analytics — architected in from day one, not bolted on later.

AI · data · connected↗
// 03 The Opportunity

The window is open — and it is open now.

Technology, supply chain, policy and unmet clinical demand are converging at the same moment.

Market growth
15–20%

CAGR for global surgical robotics, with APAC outpacing the global average.

Incumbent cost
$1–2M+

Per console robot today — the cost barrier Aevum's handheld architecture is built to remove.

Clinical anchor
1 / 14

PUTH is one of 14 national pilot hospitals for high-quality development — a top Grade 3A center.

Partnership
2025

PolyU × Peking University Third Hospital Medicine-Engineering lab — MoU signed.

Industry 5.0 momentum

AI, connectivity and human-centric automation are now mainstream — the platform for intelligent instruments exists.

GBA component ecosystem

Miniaturized motors, MCUs, batteries and sensors at production scale across the Greater Bay Area.

Policy tailwind

Explicit national support for domestic medtech and surgical robotics, with APAC growth leading the world.

Patents expiring

Early robotic-surgery patents are lapsing — a freedom-to-operate window is opening for new architectures.

Unmet hospital demand

Mid-tier and emerging-market hospitals want robotic surgery they can actually afford and deploy.

Structural drivers

Aging populations, surgeon shortages, hospital cost pressure and government investment in surgical capacity.

Where Aevum sits in the landscape

We don't compete with da Vinci on capability ceiling. We open a distinct category — competing on accessibility, capturing the tier the market leaves unserved.

Console master–slave

Intuitive (da Vinci), CMR Surgical (Versius), Medtronic (Hugo), Asensus (Senhance), Distalmotion (Dexter).

Chinese platforms

MicroPort (Toumai), Edge Medical (MP1000), Shurui Tech, Surgnova.

Aevum's position

Handheld, simplified, accessible — a distinct category rather than a head-to-head competitor on the capability ceiling, capturing the unserved tier of the market.

// 04 Roadmap

A capital-efficient bridge
to first-in-human.

The HKD 3M seed triggers the PolyU partnership and unlocks a much larger follow-on funding pipeline.

Q3 2026 Close HKD 3M seed and incorporate Aevum Surgical.
Q3–Q4 2026 Launch PolyU partnership and begin the MVP build.
Oct 2026 MVP prototype + demo ready.
Late 2026 Apply for PolyU Micro-fund and HK Science Park funding.
2027 Pre-clinical validation; HK Gov, GBA & mainland CN follow-on.
2028+ First-in-human and VC Series A.
Operating theatreOperating theatre
Empowering every surgeon · Advancing every surgery

Let's build the future
of surgery.

Subscribe to follow Aevum's progress — MVP milestones, the PolyU clinical program, and seed-round updates. For investor materials, tell us your role and we'll be in touch.